fluprednidene-acetate and Atrophy

In a multicenter double-blind study, 44 patients suffering from eczema were bilaterally treated with 0.1% fluprednidene-21-acetate over 21 days. Continuous application twice a day was compared with intermittent therapy, i.e. 1 day intermission (15 patients), 2 days intermission (16 patients) and 3 days intermission (13 patients) using the cream base. Final evaluation was based on 11 criteria. All regimens, continuous and intermittent, proved effective (at least 90% reduction of the lesions). Treatment with 3 days intermission showed the same favorable results as continuous application, although the amount of glucocorticoids applied was 75% less. Measurements of the skin fold thickness (SFT) in healthy controls did not indicate any atrophy after treatment with fluprednidene under the same conditions as the eczema patients or under occlusion for up to 21 days. Clobetasol-17-propionate, in contrast, significantly reduced the SFT already after application of only 1 week.

Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Atrophy; Child; Child, Preschool; Double-Blind Method; Drug Administration Schedule; Eczema; Female; Glucocorticoids; Humans; Male; Middle Aged; Pregnadienetriols; Randomized Controlled Trials as Topic; Skin; Skinfold Thickness